CompletedNCT05439603
ANC-501 safety and effects in adults with depression
About this title
Read the official source — NCT05439603Researchers studied ANC-501 to find out how it affected depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers studied ANC-501 to find out how it affected depression symptoms in adults with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Orange and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 19, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05439603
- Official title
Show the full official title
A Phase 2 Study of ANC-501 in the Treatment of Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Orange · Largo · Lauderhill
5 more locations
- Orlando
- Eatontown
- New York
- Staten Island
- Edmond
Questions about this study
What did researchers investigate?
Researchers studied ANC-501 to find out how it affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Did this study involve medication?
Yes. The study involved medication, including ANC-501.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
